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Composites of nanocellulose and the conductive polymer polypyrrole (PPy) are presented as
candidates for a new generation of haemodialysis membranes. The composites may combine
active ion exchange with passive ultraﬁltration, and the large surface area (about 80 m
2g
21)
could potentially provide compact dialysers. Herein, the haemocompatibilityof the novel mem-
branes and the feasibility of effectively removing small uraemic toxins by potential-controlled
ion exchange were studied. The thrombogenic properties of the composites were improved by
applying a stable heparin coating. In terms of platelet adhesion and thrombin generation, the
composites were comparable with haemocompatible polymer polysulphone, and regarding
complement activation, the composites were more biocompatible than commercially available
membranes. It was possible to extract phosphate and oxalate ions from solutions with physio-
logical pH and the same tonicity as that of the blood. The exchange capacity of the materials
wasfoundtobe600+26and706+31mmol g
21ina0.1 Msolution(pH7.4)andinanisotonic
solution of phosphate, respectively. The corresponding values with oxalate were 523+5i na
0.1 M solution (pH 7.4) and 610+1mmol g
21 in an isotonic solution. The heparinized PPy–
cellulose composite is consequently a promising haemodialysis material, with respect to both
potential-controlled extraction of small uraemic toxins and haemocompatibility.
Keywords: nanocellulose; polypyrrole; haemodialysis; biocompatibility;
heparin coating
1. INTRODUCTION
Haemodialysis remains the only treatment for patients
with chronic renal failure, who otherwise require kidney
transplantation. The normal kidney functions include
(i) ﬁltration, i.e. passive removal of metabolic toxins;
(ii) reabsorption, i.e. re-uptake of useful substances
such as water, glucose and minerals; and (iii) secretion,
i.e. active transport of metabolites from peritubular
capillaries. Therefore, haemodialysis substitutes only a
small fraction of normal kidney function and cannot
mimic the metabolic, endocrine and immune functions
of the tubule system [1]. The treatments are time-
consuming and expensive, as they require patients to
attend treatment centres three times a week, for periods
of 3–5 h under the supervision of specialized personnel
[2]. Furthermore, each treatment requires about 120 l of
highly puriﬁed water. The increasing prevalence of
kidney failure, and the shortage of organ donors further
stress the need for innovative approaches for developing
haemodialysis membranes and dialysis technology that
resembles normal renal function.
When the function of the kidneys fails, uraemic
toxins (which are normally excreted) are retained. Urae-
mic toxins can be subdivided into the following groups:
small water-soluble compounds (MW, 500 Da, proto-
type urea), middle-sized molecules (MW . 500 Da,
prototype b2-microglobulin) and protein-bound solutes
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molecules and are difﬁcult to remove by dialysis. The
failure to remove the middle-sized uraemic toxins has
been related to cardiovascular and immunological com-
plications [4]. It is important to retain proteins such as
albumin, immunoglobulins and peptide hormones
because many are essential, and losses are associated
with a great risk for the patient [5]. Therefore, one
major challenge for the development of haemodialysis
membranes is to selectively remove intermediate mol-
ecular weight (toxic) proteins in the size range of
5–35 kDa and avoid the elimination of large molecular
weight essential solutes [6].
The recent trend in the development of haemodialy-
sis systems has been to improve the ultraﬁltration
properties of the membranes by increasing the pore
size of the membrane in order to maximize the removal
of low molecular weight (toxic) proteins and to enlarge
the molecular weight spectrum of solutes removed
during dialysis treatments [1]. However, such non-
speciﬁc strategies also tend to eliminate beneﬁcial
solutes such as trace metals or medications [7].
It is also imperative to stress that the complications
associated with elevated levels of small size uraemic
toxins, such as hyperphosphataemia, hyperhomo-
cysteinaemia or hyperoxalaemia, can lead to serious
cardiovascular and immunological problems and even-
tually death [4,8]. Most patients with end-stage renal
failure have a predisposition towards elevated levels
of serum phosphorus as glomerular ﬁltration decreases.
Even with high-efﬁciency, high-ﬂux membranes,
haemodialysis fails in completely removing the dietary
load of phosphorus [9].
In the current work, we present a novel conductive
cellulose composite membrane that has the potential
of being part of a new generation of haemodialysis sys-
tems. The composite consists of nanoﬁbrous cellulose
coated with an approximately 50 nm thick layer of the
conductive polymer polypyrrole (PPy) [10] and has pre-
viously been evaluated for DNA extraction [11] and
electric energy storage [12,13].
The composite in the form of a paper sheet has a large
surface area (about 80 m
2 g
21) and extensive porosity
(about 70%) and can be used for passive ﬁltration,
considering that pristine Cladophora cellulose has been
used as a ﬁlter medium in the past [14]. However, the
greatest advantage of using this composite material is
the possibility to combine ultraﬁltration with the
electrochemical potential-controlled ion exchange prop-
erties of PPy, which are described in detail elsewhere
[15]. Brieﬂy, when a sufﬁciently positive potential is
applied, PPy is oxidized, resulting in positively charged
polymer chains and small, mobile electrolyte anions
move into the bulk material to maintain charge neu-
trality. When a sufﬁciently negative potential is
applied, the polymer is reduced and anions are released
back to the electrolyte solution [16]. It is also possible
to introduce cation exchange properties by immobilizing
large anions inside the PPy ﬁlm, as well as to introduce
speciﬁc ligands capable of highly speciﬁc ion recognition
and separation [17–19].
Active ion exchange in response to an external elec-
trical stimulus appears highly appealing for removing
solutes, and if necessary releasing medicaments, in
haemodialysis and other extracorporeal blood treat-
ments. In contrast to conventional electrodialysis,
which separates ﬂowing ions in an electric ﬁeld through
a semi-permeable membrane, the PPy ion exchange
directly incorporates ions inside the structure. Moreover,
by varying the synthesis conditions (e.g. oxidizing
agent), it may be possible to vary the network spacing
between the conductive polymer chains and, thus, pro-
mote the adsorption of low molecular size proteins
while leaving large proteins unaffected [20]. Therefore,
thepropertiesofthecompositematerialcouldpotentially
be tailored to combine active ion exchange and passive
diffusion and ultraﬁltration through the porous matrix.
The exchange process in small liquid volumes will be
fast, favouring substantial reduction of the haemodialy-
sis sessions. Moreover, the large surface area of the
composite material might lead to a new generation of
compact dialysers.
An important requirement for dialysis membranes
is haemocompatibility. Blood interaction with the
haemodialysis membranes leads to a series of inter-
linked events such as protein adsorption, platelet and
leucocyte adhesion/activation, complement system
activation and activation of the coagulation cascade
[21]. The activation of circulating blood leucocytes
and platelets leads to upregulation of adhesion recep-
tors and release of active species such as cytokines,
growth factors and activator factors which in turn can
promote further cell activation and adhesion. The
complement system plays a central role in leucocyte
activation and in the establishment of an inﬂammatory
state [22]. In the chronic haemodialysis patient, these
interactions are repetitive, and even mild interac-
tions may lead to adverse clinical consequences, such
as haematological changes in the patient blood status
(e.g. leucopaenia) and immunological dysfunction [23].
Currently available haemodialysis membranes not only
present different physicochemical properties such as per-
formance, pore size and adsorptive capacities, but also
show different grades of haemocompatibility. The
reason for this is not only differences in chemical compo-
sition, but also in the surface roughness, manufacturing
conditions and sterilization techniques [1,24].
Several studies have shown the non-cytotoxic nature
and good biocompatibility of PPy and its derivatives
when tested with a wide number of cell types [25,26].
StudiesbyMao etal.[27]andZhangetal.[28]highlighted
thegoodbloodcompatibilityofPPy-basedmaterials.The
aims of the present work were to investigate the haemo-
compatibility of a novel PPy–nanocellulose composite
material and to study the feasibility of effective removal
of small size model uraemic toxins, phosphate and
oxalate, by potential-controlled ion exchange.
2. MATERIAL AND METHODS
2.1. Preparation of PPy–cellulose composites
The PPy–cellulose composites were prepared as
previously described [26]. Brieﬂy, chemical polymeriz-
ation of pyrrole on Cladophora sp. algae cellulose
ﬁbres was carried out with FeCl3 as the oxidizing
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deionized water, followed by 5 l of 0.1 M NaCl at a
rate of 7 l h
21. After the rinsing step, 8 g of 3 per cent
(w/v) microﬁbrillated cellulose (MFC) was added,
and the mixture was ultrasonicated for 1 min. The pro-
duct was then ﬁltered and dried to obtain 1–2 mm thin
composite sheets.
A set of lightly rinsed composite samples, rinsed with
10 l of 0.1 M NaCl, was also prepared for the feasibility
studies.
The composite materials were ﬁnally incubated with
Hank’s balanced salt solution (HBSS) for 48 h at room
temperature.
2.2. Heparinization
In the present work, the Corline method (Corline Sys-
tems AB, Uppsala, Sweden) was used to heparin coat
the composite materials, the blood collecting tubes
and the slide chambers. The Corline heparin-coating
process includes a conditioning layer of a polymeric
amine (PAV, proprietary agent Corline, Sweden), onto
which a macromolecular heparin conjugate is attached
by multiple ionic interactions. In the heparin conjugate,
approximately 70 heparin molecules are covalently
linked to a polymeric carrier. Thereby, the antithrom-
bin (AT)-binding sequence is left intact to interact
with AT [29]. The heparin coating applied to the com-
posite materials was a modiﬁcation of the Corline
heparin surface. The composite material is positively
charged (PPy is in its oxidized state), and therefore
the conditioning layer of the PAV is not needed.
For that reason, the protocol used to heparin-coat
the composite surface consisted of the application of
the heparin conjugate, followed by an incubation step
with PAV and a second layer of heparin conjugate.
The heparinization of the composite membranes was
evaluated by the AT binding assay (see below) and by
ﬂuorescence microscopy. The heparinized composite
membranes were repeatedly reduced and oxidized by
cyclic voltammetry (CV) to evaluate the stability of
the heparin coating. The effect of the composite steam
sterilization by autoclaving (1.5 MPa for 20 min) on
the heparin coating was studied by means of the AT
binding assay.
2.2.1. Antithrombin binding assay
The AT binding capacity refers to the ability of heparin
to interact with the coagulation regulator AT. As a
result of the heparin–AT interaction, AT adopts a
more active state, increasing its ability of inhibiting
different coagulation factors [30]. The AT binding
capacity of the heparin-modiﬁed composites was evalu-
ated as described by Kodama et al.[ 31]. This method is
based on the inhibition of factor Xa by AT in the pres-
ence of heparin. The heparin-coated membranes were
pre-soaked in phosphate-buffered saline (PBS) and
incubated with normal citrate plasma. The membranes
were then rinsed with Tris–NaCl (50 mM Tris–HCl,
pH 7.8, 0.15 M NaCl) followed by the elution of AT
by Tris–NaCl containing 150 IU ml
21 heparin (Leo
Pharma A/S, Ballerup, Denmark). The AT activity of
the eluate was determined in a factor Xa assay.
Factor Xa (Chromogenix, Mo ¨lndal, Sweden) was
added to the sample, incubated for 5 min, followed by
the addition of the chromogenic substrate S-2765
(Chromogenix). After 5 min, the reaction was termi-
nated by the addition of citric acid and the remaining
factor Xa activity was measured at 405 nm. A cali-
bration curve with normal citrate plasma was used to
determine the concentration of AT. The results were
expressed as picomoles of AT per centimetre square.
2.2.2. Fluorescence microscopy
The heparin coating was visualized by ﬂuorescence
microscopy. The heparinized composite membranes
were incubated with avidin conjugated with Texas
Red-X according to the kit from Molecular Probes
(Invitrogen, Eugene, OR, USA) diluted to 15 mgm l
21
in saline solution for 30 min, followed by a washing
step with deionized water. The rationale for using
avidin–Texas Red is that avidin binds to heparin
owing to heparin binding domains in avidin. Samples
were observed under a ﬂuorescence microscope (Nikon
Eclipse E600, Tokyo, Japan).
2.3. Potential-controlled ion exchange
CV was performed in a three-electrode setup using the
composite samples as the working electrode, an Ag/
AgCl reference electrode and a platinum wire counter
electrode. The dried composite samples were attached
to a platinum wire sample holder. For each sample, 10
cycles were performed, each including reduction fol-
lowed by oxidation. The scan rate was 5 mV s
21 and
the experiments were performed with an Autolab
potentiostat (Eco Chemie, The Netherlands).
2.3.1. Stability of heparin coating
The heparin coating stability during electrochemical
cycling was studied using heparinized samples which
were cycled in 2 M NaCl between 20.6 V and 0.6 V
versus Ag/AgCl. The samples were thereafter dried and
analysed with the AT binding assay and ﬂuorescence
microscopy, as described earlier.
2.3.2. Feasibility study
Non-heparinized and heparinized samples were CV-
cycled between 20.8 V and greater than or equal to
0.3 V versus Ag/AgCl; the anodic turning potential
was adjusted for each sample to result in a complete oxi-
dation peak and to avoid overoxidation [32]. The samples
were cycled in pure 0.10 M oxalate (Na2C2O4,B D HP r o -
labo) and phosphate (NaH2PO4, BDH Prolabo)
solutions, adjusted to pH7.4 with NaOH. Samples
were also cycled in pure isotonic solutions of oxalate
(0.12 M, pH7.3) and phosphate (0.15 M KH2PO4,p H
4.4; Sigma-Aldrich, Inc., St Louis, MO, USA). Charge
capacities, Q (expressed as Coulomb per gram of
sample), were calculated from the 10th scan for each
sample, by integrating the current over time from the
ﬁrst point of positive current to the current minima
located at a more positive potential than the oxidation
peak (before overoxidation becomes signiﬁcant; see
arrows in ﬁgure 2). The approximate ion exchange
capacity (mol g
21 sample) was calculated from the
Cellulose–polypyrrole dialysis membranes N. Ferraz et al. 1945
J. R. Soc. Interface (2012)charge capacity, assuming the same distribution of differ-
ently charged anions in the material as in the electrolyte.
The distribution was calculated from the Henderson–
Hasselbalch equation, as shown in equation (2.1).
A
B
¼ 10pKa pH; ð2:1Þ
where A corresponds to the acid, and B the base of the
acid–base pair. For a solution containing ions A and B
with charges 21 and 22, respectively, theircontribution
to the charge capacity is then given by equation (2.2).
Q ¼ A þ 2B: ð2:2Þ
Solving for A and B gives the number of moles of
each anion that is incorporated per gram of sample, as
given by equations (2.3) and (2.4).
A ¼
10pKa pHQ
ð2 þ 10pKa pHÞeNA
ð2:3Þ
and
B ¼
Q
ð2 þ 10pKa pHÞeNA
; ð2:4Þ
where NA is Avogadro’s number and e is the charge of
an electron. The total ion exchange capacity, C
(mol g
21), is then given by equation (2.5).
C ¼ A þ B: ð2:5Þ
The different pKa values were retrieved from SI
chemical data [33]. As follows from equation (2.1),
both oxalate solutions contained only (COO
2)2, the
isotonic phosphate solution contained only H2PO
 
4
while the 0.10 M phosphate solution contained both
H2PO
 
4 and HPO
2 
4 , in signiﬁcant amounts.
2.4. Blood compatibility study
2.4.1. Blood sampling
Fresh human blood from 10 healthy donors was collected
in heparin-coated 50 ml Falcon tubes (Becton–Dickin-
son, USA) containing soluble heparin (Leo Pharma),
giving a ﬁnal concentration of 1.5 IU heparin ml
21.
2.4.2. The slide chamber model
The slide chamber previously described by Hong et al.
[34] was used for these experiments. The device is manu-
factured from polymethylmethacrylate and consists of
two wells that can hold a maximum volume of 1.6 ml
each. After heparin coating, each well was ﬁlled with
1.4 ml of blood (1 ml of blood was also collected in
Eppendorf tubes containing ethylenediaminetetraacetic
acid (EDTA)–K3 or heparin; the latter samples were
later used as 0 min controls). The composite membranes
(previously soaked in saline solution) were then placed so
as to cover the wells (as ‘lids’), thus two circular
chambers were created. The slide chambers were rotated
vertically at 22 rpm for 60 min in a 378C water bath.
After incubation, 0.6 ml of blood from each chamber
was removed and mixed with EDTA–K3 or heparin,
giving a ﬁnal concentration of 10 mM or 10 IU ml
21,
respectively. The EDTA samples (including the 0 min
controls) were analysed for platelet numbers on a
Coulter Ac.T diff haematology analyser (Coulter Cor-
poration, Miami, FL, USA). Thereafter, the samples
were centrifuged at 3000 g for 10 min at 48C, and the
plasma was collected and stored at 2708Cf o rf u t u r e
analysis. The heparin-treated blood samples were ana-
lysed by ﬂow cytometry. The membranes were ﬁxed
and dehydrated prior to the scanning electron
microscopy (SEM) studies.
Three different types of commercially available haemo-
dialysis membrane materials were also included in the
blood compatibility study: unmodiﬁed regenerated cellu-
lose (RC), modiﬁed cellulose and a synthetic polymer.
Thus, the following materials were used as references: RC
(SartoriusStedimBiotechGmbH,Goettingen,Germany),
celluloseacetate (CA;SartoriusStedim Biotech)and poly-
sulphone (PS; Pall Life Science, USA), all membranes had
pore sizes of 0.20 and 0.45 mm. All materials were run in
duplicate. Although unmodiﬁed RC is rarely used today
in haemodialysis, it is a valuable reference material for
comparative studies in the context of the present work.
2.4.3. Enzyme immunoassays
PBS containing 1 per cent (w/v) bovine serum albumin
(BSA; Sigma-Aldrich), 0.1 per cent Tween 20 (Sigma-
Aldrich) and 10 mM EDTA was used as the working
buffer, while PBS containing 0.1 per cent Tween 20
served as the washing buffer.
Detection of C3a. Plasma samples diluted 1/1000
or 1/5000 were incubated in wells coated with mono-
clonal antibody 4SD17.3 (capture antibody). C3a was
detected with biotinylated anti-C3a antibody (Dako,
Glostrup, Denmark) followed by horse radish peroxi-
dase (HRP)-conjugated streptavidin (GE Healthcare,
Uppsala, Sweden) [35]. Zymosan-activated serum, cali-
brated against a solution of puriﬁed C3a, served as a
standard. The values were given in ng ml
21.
Detection of sC5b-9. sC5b-9 was measured using a
modiﬁcation of the method described by Mollnes et al.
[36]. Plasma samples were diluted 1/3 and added to
microtitre plates coated with antineoC9 monoclonal
antibody. sC5b-9 was detected by polyclonal anti-C5
antibodies diluted 1/500 (Dako, Glostrup, Denmark),
followed by HRP-conjugated anti-rabbit immunoglobu-
lin diluted 1/500 (Dako, Glostrup, Denmark). Zymosan
activated serum containing 40000 AU ml
21 served as
standard. The values were presented as AU ml
21.
Detection of thrombin–antithrombin complex
(TAT). Microtitre plates were coated with anti-human
thrombin antibody (Enzyme Research Laboratories,
South Bend, IN, USA) diluted 1/125. HRP-coupled
anti-human AT antibody (Enzyme Research Labora-
tories) diluted 1/125 was used for detection. Pooled
human serum diluted in normal citrate–phosphate–
dextrose plasma was used as a standard. The values
were presented as mgl
21.
2.4.4. Flow cytometry
Samples for ﬂow cytometry were collected in heparin
(10 IU ml
21) and treated with human immunoglobulin
(Beriglobin, ZLB Behring GmbH, Marburg, Germany),
4m gm l
21,toblockFcreceptors.Stainingwasperformed
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incubation at 48C for 30 min, the samples were treated
with Erythrolyse red blood cell lysing buffer (AbD Sero-
tec, Oxford, UK) for 10 min. After centrifugation (400 g,
5 min), cell pellets were resuspended in PBS containing 1
per cent BSA and again centrifuged for 5 min at 400 g.
Finally, the cells were resuspended in PBS and analysed
using a BD LSRII SORP (BD Biosciences, CA, USA)
ﬂow cytometer. Monocytes and neutrophils were ident-
iﬁed by their distinct patterns on forward scatter and
side scatter and by appropriate surface markers. For
monocyte identiﬁcation, monoclonal FITC-conjugated
anti-CD14 was used, while for neutrophil identiﬁca-
tion monoclonal allophycocyanin (APC)-conjugated
anti-CD15 was applied. Monoclonal PE-conjugated
anti-CD11b was used to evaluate the upregulation of
CD11b expression on monocytes and neutrophils.
The antibodies for negative controls were mouse APC
IgM kappa isotype control, PE mouse IgG1 kappa iso-
type control and FITC mouse IgG2b kappa isotype
control. All antibodies were supplied by BD Biosciences.
The setting of ﬂow cytometry compensation was per-
formed using the AbC anti-mouse bead kit (Invitrogen,
UK). AbC capture beads were single stained with the
same ﬂuorochrome-labelled antibodies used for cell
staining, following the manufacturer’s recommendations.
Data were analysed using a BD FACSDiva software
(BD Biosciences). The mean ﬂuorescence intensity of
the staining of PE-conjugated anti-CD11b on mono-
cytes and neutrophils was calculated by the software.
2.4.5. Scanning electron microscopy
After blood contact, the composite membranes were
washedwithHBSS,ﬁxedwith1.5percent (v/v)glutaral-
dehyde in HBSS, dehydrated through a series of ethanol
concentrations (25, 50, 70, 80, 90 and 100% (v/v)), and
followed by incubations with haexamethyldisilazane
(HMDS) solutions (HMDS:ethanol 1:2, HMDS:
ethanol 2:1 and 100% HMDS). Finally, the dehydrated
samples were allowed to air-dry and were then kept in a
desiccator prior to SEM analysis using a Leo 1550 SEM
instrument (Zeiss, Germany).
2.4.6. Statistical analysis
Non-parametric statistical analyses were performed
using IBM SPSS Statistics v. 19. Data were statistically
evaluated by independent samples median tests with
pairwise comparisons of groups, adjusted for multiple
comparisons. Samples were considered statistically
different at p , 0.05.
3. RESULTS AND DISCUSSION
3.1. Heparinization
Modiﬁcation of biomaterial surfaces with heparin is a
well-established method to improve blood compatibility
[29,37–39]. It is important to ensure that the AT binding
sequence of heparin is left intact after heparin has been
immobilized on the surface, and to control the stability
of the heparin coating.Thereleaseof heparin duringhae-
modialysis is particularly undesirable because a large
amount of heparin may enter the blood circulation and
this can increase the risk of abnormal haemorrhage or
lead to heparin-induced thrombocytopaenia [40]. As
shown in table 1, heparin was successfully immobilized
on the composite surface, exhibiting an AT binding
capacityof 9+1p m o lc m
22. This value was statistically
signiﬁcant different from the negative control (non-
heparinized composite), which showed 2+1p m o lc m
22
owing to unspeciﬁc binding. The heparin coating applied
to the composite membranes is due to electrostatic inter-
actions. The heparin conjugate binds strongly to the
cationic surface of the composite (oxidized PPy) as a
result of the multiplicityof anionic groups on the heparin
conjugate. When PPy is subjected to reduction and oxi-
dation cycles, a certain loss of heparin could be expected
because the reduction of the conductive polymer renders
the material neutral in terms of charge. However, the
macromolecular characteristics of the heparin conjugate,
togetherwith thepresenceof the polyamineanda second
layeroftheheparinconjugate,seemstopreventdepletion
of the heparin coating after the cyclic reduction–
oxidation treatment, as indicated by the AT binding
capacityofsuchsample(9+1p m o lc m
22).Fluorescence
microscopic images of the heparinized composite indi-
cated the presence of the heparin coating on the
material surface (ﬁgure 1a). The heparin layer remained
on the membrane surface after repeated reduction–
oxidation cycles of the heparinized composite (ﬁgure 1b).
Theimage inﬁgure 1c showed the absenceof non-speciﬁc
avidin-binding or autoﬂuorescence of the composite
surface because no prominent ﬂorescence signal could
be detected.
Theeffectofsteamsterilizationontheheparincoating
wasalsostudiedbyevaluatingtheATbindingcapacityof
(a) (b) (c)
Figure 1. Heparin coating on the PPy–cellulose membranes stained with avidin–Texas Red observed under ﬂuorescence
microscopy. Panels show representative images of (a) heparinized PPy–cellulose, (b) heparinized PPy–cellulose after
reduction–oxidation cycles, (c) non-heparinized PPy–cellulose membrane. Note the intense red staining distributed all over
the surface of the heparinized samples (a,b). (Online version in colour.)
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indicated that the active properties of the heparin layer
were unaffected by the autoclave process, because the
AT binding capacity was found to be 8+2p m o lc m
22
and not signiﬁcantly different form the value found
for the heparinized sample before steam sterilization
(p . 0.05; table 1).
Other authors [41,42] have successfully modiﬁed PPy
surfaces with heparin, with the aims of improving blood
compatibility and stimulating endothelial cell growth.
Li et al.[ 41] claimed that covalent bonding of heparin
is the most effective method to heparin coat PPy. The
authors mentioned that the main disadvantage of
ionic immobilization of heparin onto PPy was the loss
of heparin over time, while electrochemical entrap-
ment of heparin could lead to reduced bioactivity of
the entrapped heparin [41]. Nevertheless, thanks to
the properties of the Corline heparin conjugate, we
have shown that it is possible to immobilize heparin
through ionic interactions onto PPy with the method
described here, and that this gives rise to a stable and
active heparin coating.
3.2. Feasibility study
The PPy–cellulose composite is a material combining
the porous structure and large surface area of Clado-
phora cellulose [43] with the potential-controlled ion
exchange capabilities of PPy [44]. Thus, with a PPy–
cellulose composite in a haemodialysis setting, in
addition to passive diffusion and ultraﬁltration through
the porous structure of the cellulose, solutes can be
extracted by a potential-controlled ion exchange mech-
anism. To the authors’ knowledge, this is the ﬁrst study
to investigate the ion exchange properties of a PPy–
cellulose composite with respect to removal of speciﬁc
uraemic toxins. Phosphate and oxalate were chosen as
model solutes for testing the material’s capability to
extract solutes relevant in haemodialysis. The removal
of phosphate in patients undergoing dialysis is insufﬁ-
cient, resulting in hyperphosphataemia. In fact, the
average blood serum concentrations of phosphate has
been found to be 6.2 mg dl
21 in end-stage renal disease
(ESRD) patients that have undergone dialysis for at
least 1 year [45], while the normal range for healthy
individuals is 2.6–4.5 mg dl
21 [46]. Serum phosphate
concentrations of 5 mg dl
21 or higher are related to an
increased mortality risk [47]. Elevated oxalate concen-
trations in the blood (hyperoxalaemia) can lead to
deposition of calcium oxalate in various tissues, includ-
ing the heart [48]. In ESRD patients, it has been found
that the average uraemic concentration is 4.9+
1.4 mg l
21, whereas the normal concentration is 0.3+
0.1 mg l
21 [49,50]. The ratio between the average urae-
mic and normal concentration was found to be among
the 20 highest scoring solutes out of 45, highlighting
oxalate as one of several solutes associated with uraemic
toxicity [50].
The capacity of the novel material to extract phos-
phate and oxalate ions was studied by CV-cycling of
the composite samples in different phosphate and oxa-
late solutions. A representative cyclic voltammogram,
resulting from CV-cycling of a heparinized sample in
an isotonic oxalate solution (0.12 M, pH 7.3), is shown
in ﬁgure 2. Notable features include the oxidation
peak situated at approximately 0.05 V versus Ag/
AgCl and the reduction peak located around 20.45 V
versus Ag/AgCl. The peaks show that the PPy layer
is indeed oxidized and reduced and, as a result, oxalate
ions move in and out of the material, respectively.
We cannot, however, rule out completely that some
cations participate in the oxidation and reduction
process. Similar voltammograms were obtained with
heparinized and non-heparinized samples in isotonic
or 0.10 M solutions of phosphate or oxalate, and
only minor differences were observed between the
electrolyte solutions.
Theextractioncapacityofthematerialwithrespectto
the studied ions was calculated based on the oxidation
charge obtained from the CVs (ﬁgure 3), assuming no
contribution from cation movements. It should be
pointed outthat thecapacityof the materialis afunction
of the conductivity and concentration of the electrolyte
solution [20,51]. Thus, the calculated capacity does
not necessarily reﬂect the true capacity in a haemodialy-
sis application. However, the capacities are useful for
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Figure 2. A representative cyclic voltammogram of the 10th
cycle of a heparinized sample in an isotonic oxalate solution
(0.12 M, pH 7.3) showing oxidation and reduction peaks cor-
responding to the incorporation and expulsion, respectively, of
oxalate ions by the PPy–cellulose material. The arrows indi-
cate the positions of the ﬁrst point of positive charge and the
local minima following the oxidation peak, which were used as
limits for calculations of ion exchange capacities.
Table 1. Evaluation of heparin coating on PPy–cellulose
composites.
AT binding capacity
(pmol cm
22)
a
heparinized composite 9+1
heparinized composite after
redox cycle
9+1
heparinized composite after
steam sterilization
8+2
non-heparinized composite 2+1
aData represent mean value+s.e. of the mean, n ¼ 6.
1948 Cellulose–polypyrrole dialysis membranes N. Ferraz et al.
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non-heparinized samples. No statistically signiﬁcant
capacity difference (p . 0.05) was observed between
non-heparinized and heparinized samples cycled in a
0.10 M phosphate solution (pH 7.4; 587+23 and
600+26 mmol g
21, respectively) or an isotonic phos-
phate solution (711+44 and 706+31 mmol g
21,
respectively). There was also no signiﬁcant difference
(p . 0.05) between the non-heparinized andheparinized
samples when oxalate was extracted from the 0.10 M
solution (pH 7.4; 579+26 and 523+5 mmol g
21,
respectively) or from the isotonic solution (692+50
and 610+1 mmol g
21, respectively). These results
demonstrate that it is possible to extract phosphate and
oxalate ions from solutions with physiological pH and
the same tonicity as blood. It should be noted that the
data in this study are solely based on the extracted
charges and that in order to get the exact number of
extracted anions of each type, one needs to directly
measure the amounts of anions actually extracted.
The key point is, however, that heparinizing the PPy–
cellulose composite has no effect on the material’s
extraction capacity.
The feasibility study illustrates that heparinized
PPy–cellulose composites may possibly be used as a
potential-controlled uraemic toxin extraction mem-
brane, where solutes are removed also by extraction
into the material. Further investigations into the appli-
cability of the PPy–cellulose material will include
physiological solute concentrations, mixed solvents,
whole blood and eventually ﬂowing blood. Moreover,
investigations related to diffusion and ultraﬁltration of
non-ionic molecules through the porous matrix are cur-
rently underway. It should be mentioned that the
ability of PPy to extract molecules from a blood ﬂow
has been demonstrated recently, where a PPy-based
in vivo microextraction technique was used to extract
pharmaceutical substances [52]. Furthermore, the
material’s capability of releasing solutes in response to
an electrical stimulus should be explored because this
property provides a possibility of designing new haemo-
dialysis systems that could mimic the secretion function
of the kidneys.
3.3. Blood compatibility study
The in vitro model used in this work makes it possible
to analyse both the biomaterial surface in terms of
cell adhesion and the cellular and molecular events
that take place in the ﬂuidic phase. Blood was collected
in tubes containing soluble heparin at a ﬁnal concen-
tration of 1.5 IU ml
21. This heparin concentration
simulates that in clinical dialysis and reﬂects appro-
priate anticoagulation, e.g. minimize changes in
coagulation parameters while avoiding total depletion
of platelets [24]. Three groups of haemodialysis mem-
branes can be differentiated according to the raw
materials used to manufacture them: unmodiﬁed RC,
substituted cellulose and synthetic polymers. One mem-
brane of each group was included in this study to
compare their in vitro haemocompatibility with the per-
formance of the novel PPy–cellulose haemodialysis
membrane. Pore sizes of high cut-off membranes, typi-
cally larger than 200 nm, were selected [1]. The
composite material has a broad pore size distribution
in the mesopore range, i.e. between 2 and 100 nm,
both in its heparinized and non-heparinized form as evi-
denced from the density function theory (DFT) analysis
of N2 sorption isotherms (see electronic supplementary
material, ﬁgure S1). It is seen from the DFT analysis
that the pore size distribution in the samples is mark-
edly skewed towards larger pore sizes. The latter is in
line with the high-resolution SEM micrographs (see
electronic supplementary material, ﬁgure S2), in
which pores having widths of up to around 200 nm
are clearly visible. It should be pointed out that no
efforts have yet been made to obtain a narrow pore
size distribution in the composite around a speci-
ﬁc cut-off value, and this issue will be addressed in
future work.
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Figure 3. Ion exchange capacities calculated from the voltammograms, taking into account the distribution of ions in the solution
at the corresponding pH for non-heparinized (NH) and heparinized samples (H). Panels show capacities in (a) 0.10 M (black bars;
pH 7.4) and isotonic (grey bars; 0.15 M, pH 4.4) phosphate solutions and (b) 0.10 M (black bars; pH 7.4) and isotonic (grey bars;
0.12 M, pH 7.3) oxalate solutions. No signiﬁcant differences in capacity were observed between non-heparinized and heparinized
samples. The values are expressed as the mean+s.e. of the mean, n ¼ 3.
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the thrombogenic properties of the dialysis membranes,
i.e. evaluation of platelet number and adhesion and the
formation of TAT complexes, together with the study of
complement activation and the upregulation of CD11b
receptor expressed on neutrophils and monocytes.
3.3.1. Thrombogenic properties
Platelet counts were performed after blood contact with
the studied materials and the results were expressed as
percentage of the values obtained for the initial blood
sample (0 min control; ﬁgure 4). The results indicated
a marked reduction on platelet number when blood
was in contact with the non-heparinized composite
material. However, the heparin coating was very effec-
tive in improving blood compatibility in terms of
reduction in platelet number (57+3% versus 20+
3%). The percentage of platelet reduction observed
with the heparin-coated membranes was compara-
ble with the values obtained with the reference
materials, i.e. no statistically signiﬁcant difference
was found between the reference materials and the
heparinized composite. The comparison between the
heparinized PPy–cellulose membrane before and after
repeated reduction and oxidation cycles conﬁrmed the
stability of the heparin coating, because no signiﬁcant
difference in platelet reduction was found between
these samples. Platelets are thought to become
activated when they come in contact with an artiﬁcial
surface, and their number decreases as they adhere
to the material surface and aggregate. When the
heparin-coated composite surface was studied using
SEM, the images conﬁrmed the poor platelet adhesion
on the material surface (ﬁgure 5a). The same pattern
was observed on the heparinized sample after reduction
and oxidation cycles (ﬁgure 5b). However, SEM micro-
graphs of the non-heparinized composites showed a large
number of platelets and a mesh of ﬁbrils (ﬁgure 5c).
The formation of thrombin was followed by measur-
ing the TAT levels after blood contact with the studied
materials, and the results showed that the thrombo-
genic properties of the heparinized composite were
comparable with those of the reference materials
(ﬁgure 6), while the non-heparinized material showed
signiﬁcantly higher thrombin generation. The level
of TAT complex generated by the non-heparinized
PPy–cellulose membrane was (10 670+1269 mgl
21).
High platelet consumption can be related to the par-
allel thrombin generation because thrombin is a platelet
activator. In addition, activated platelets induce throm-
bosis by secretion of bulk phase agonists, acceleration
of thrombin formation and via ﬁbrinogen-mediated
platelet–platelet aggregation [21,53]. The non-coated
composite material was found to be highly thrombo-
genic as reﬂected by the high reduction in platelet
count, large platelet adhesion to the material surface
and elevated levels of TAT. However, when the compo-
site surfaces were coated with heparin conjugate, the
formation of thrombin was signiﬁcantly reduced and
so was the adhesion of platelets to the biomaterial sur-
face. Soluble heparin downregulates coagulation by
binding to AT and turning it into a more active state,
increasing the ability to inhibit different coagulation
factors by 1000-fold [54]. The accepted theory behind
the use of heparin coatings is that downregulation of
coagulation is achieved by binding the regulator AT
[22]. Nilsson et al.[ 55] proposed that the effect of
heparin coating is that it turns the biomaterial surfaces
into surfaces totally devoid of adsorbed host cells and
platelets after contact with blood. The latter authors
suggested that plasma protein binding to the heparin-
coated surface is due to both non-speciﬁc and speciﬁc
interactions and that the binding does not signiﬁcantly
change the conformation of the adsorbed proteins,
which, hence, are not activated. In the case of platelet
adhesion and subsequent activation by artiﬁcial sur-
faces, the conformation of adsorbed ﬁbrinogen plays
an important role [56]. Therefore, it can be speculated
that the heparin coating not only suppresses the throm-
bin formation by its high AT binding capacity but also
decreases platelet adhesion and activation because
adsorbed ﬁbrinogen on the heparin surface does not
adopt the right conformation, i.e. does not expose
platelet-binding sites.
3.3.2. Complement activation
Complement activation products C3a, C4a and C5a are
used as candidates to evaluate complement activation
in plasma samples. The C3a level is usually chosen as
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Figure 4. Platelet counts performed after whole-blood
incubation with the studied materials (soluble heparin concen-
tration 1.5 IU ml
21). The reduction in platelet number is
expressed as percentage of the values obtained for the 0 min
samples. A signiﬁcant improvement in platelet reduction is
achieved by heparin coating the composite material. Results
also indicated the stability of the heparin coating when the
heparinized composite is repeatedly reduced and oxidized. The
values represent the mean+s.e. of the mean from experiments
usingbloodfrom10differentdonors.(H,heparinizedcomposite;
H Red-Ox, heparinized composite after reduction–oxidation
cycles; NH, non-heparinized composite; CA, cellulose acetate;
RC, regenerated cellulose; PS polysulphone, 0.2 represents 0.2
mm pore size and 0.45 indicates membranes with 0.45mm
pore sizes).
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most potent anaphylatoxin but has the disadvantage of
rapidly being coupled to its receptor. However, measur-
ing of sC5b-9 is an excellent way to quantify terminal
complement activation and indirectly assess C5a levels
[57]. The novel PPy–cellulose haemodialysis membrane
showed signiﬁcant lower levels of C3a than the commer-
cially available membranes CA (ﬁgure 7a). When
measuring the levels of sC5b-9, we found that the com-
posite membrane generated signiﬁcant lower levels than
the reference membranes CA, RC and PS (ﬁgure 7b).
The presence of PPy coating on the cellulose ﬁbres
could explain the lower complement activation as it
covers the OH groups on the cellulose. The signiﬁcantly
higher complement activation found for pure Clado-
phora cellulose/MFC membranes supports this
hypothesis (C3a ¼ 2370+172 ng ml
21, sC5b-9 ¼
322+49 AU ml
21).
We found unexpected high levels of C3a and sC5b-9
after blood contact with PS, a material commonly
regardedashighlybiocompatible.However,thedifference
in biocompatibility could be related to the models used in
different studies (in vitro versus in vivo or ex vivo,s e m i -
static model versus dynamic blood recirculation) and
the material design (membrane versus hollow ﬁbres)
[58–61]. Moreover, when used in dialysers, PS is com-
bined with hydrophilic additives or is processed with
hydrophilic copolymers such as methallylsulphonate to
compensate for its hydrophobicity [1]. Therefore, this
difference in chemical composition could also contribute
to the observed difference between the results of the
present study and those of the others [58–61].
3.3.3. Upregulation of CD11b on neutrophils and
monocytes
An effect of complement activation is the upregulation
of receptors on leucocytes such as CD11b/CD18 and
CD35—which together with the down regulation of
L-selectin—make the leucocytes very adhesive and
prone to interact with platelets and endothelial cells
[22].Thismayplayanimportantroleinthepathophysio-
logicalchangesthatoccurduringahaemodialysissession.
All studied materials showed an increase in CD11b
expression, both in neutrophils and monocytes (ﬁgure 8a
and b, respectively) after 60 min incubation with blood.
However, such increase showed to be non-signiﬁcant
when statistically evaluated. The limitations of the non-
parametric test, i.e. the use of ranks instead of continuous
values, may mask the large differences that we actually
see between the initial CD11b expression and the
values obtained with the studied materials. The evalu-
ation of CD11b expression in neutrophils and monocytes
did not show any signiﬁcant difference between the
studied membranes (ﬁgure 8a and b, respectively).
Thus, the differences found in complement activation
between the studied materials were not reﬂected in the
upregulation of CD11b expression. These results reﬂect
the complexity of biochemical interactions at the blood–
membraneinterface and the importance ofthe evaluation
of multiple parameters.
In summary, a set of haemocompatibility parame-
ters were taken into account to evaluate the activation
of blood after contact with the novel PPy–cellulose
10 mm
(a)( b)( c)
10 mm 10 mm
Figure 5. Representative scanning electron micrographs of PPy–cellulose membranes after 60 min incubation with whole blood
(soluble heparin concentration 1.5 IU ml
21). The heparinized composites (before and after reduction–oxidation cycles, (a) and
(b), respectively), showed minimal cell adhesion on the surfaces, while the non-heparinized composite presented a large number of
adherent platelets and a mesh of ﬁbrils (c).
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Figure 6. Thrombin–antithrombin complex (TAT) levels
detected in the ﬂuid phase after whole-blood (soluble heparin
concentration 1.5 IU ml
21) contact with the heparinized
PPy–cellulose membranes and the reference materials. The
level of TAT complex generated by the non-heparinized
PPy–cellulose membrane was (10670+1269 mgl
21) and sig-
niﬁcantly higher than the heparinized composites and the
reference materials. This value was omitted in the ﬁgure for
clarity. No signiﬁcant difference was found between the hepar-
inized composites and the reference materials. The values
represent the mean+s.e. of the mean from experiments using
blood from 10 different donors. (H, heparinized composite; H
Red-Ox, heparinized composite after reduction–oxidation
cycles; CA, cellulose acetate; RC, regenerated cellulose; PS
polysulphone,0.2represents0.2 mmporesizeand0.45indicates
membranes with 0.45 mm pore sizes.)
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J. R. Soc. Interface (2012)haemodialysis membrane. By including reference haemo-
dialysis membrane materials, we were able to compare
the biocompatible proﬁle of the novel material with
those of the well-established haemodialysis membranes.
In terms of platelet adhesion and thrombin generation,
the composite material proved to be highly thrombo-
genic, which—to a large extent—could be eliminated
by applying a stable heparin coating. The heparinized
composites behaved in the same way as the synthetic
polymer PS. It is reasonable to assume that the heparin
coating on the composite material can be further
optimized leading to further improvement. When comp-
lement activation was evaluated in terms of sC5b-9
levels, the composites (uncoated and heparin-coated)
were shown to be more biocompatible than the reference
materials. In terms of upregulation of the adhesion
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Figure 7. Complement activating properties of the PPy–cellulose composites and the reference materials after 60 min whole-
blood incubation (soluble heparin concentration 1.5 IU ml
21). The novel PPy–cellulose haemodialysis membrane showed
signiﬁcant lower levels of C3a (a) than the commercially available membranes CA and signiﬁcant lower levels of sC5b-9
(b) than the reference membranes CA, RC and PS. The values represent the mean+s.e. of the mean from experiments using
blood from 10 different donors. (H, heparinized composite; H Red-Ox, heparinized composite after reduction–oxidation
cycles; NH, non-heparinized composite; CA, cellulose acetate; RC, regenerated cellulose; PS polysulphone, 0.2 represents
0.2 mm pore size and 0.45 indicates membranes with 0.45 mm pore sizes.)
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Figure 8. Modulation of neutrophil (a) and monocyte (b) CD11b expression after 60 min whole-blood incubation with the PPy–
cellulose membranes and the reference materials (soluble heparin concentration 1.5 IU ml
21). The results are expressed as mean
ﬂuorescence intensity+s.e. of the mean (n ¼ 6). The evaluation of CD11b expression in neutrophils and monocytes did not show
any signiﬁcant difference between the studied membranes. (H, heparinized composite; H Red-Ox, heparinized composite after
reduction–oxidation cycles; NH, non-heparinized composite; CA, cellulose acetate; RC, regenerated cellulose; PS polysulphone,
0.2 represents 0.2 mm pore size and 0.45 indicates membranes with 0.45 mm pore sizes.)
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tivity of the composite membrane was similar to the
reference materials.
The in vitro model presented in this work allowed for
initial screening of the promising composite membrane
material. Next steps will involve the use of ex vivo ﬂow
systems to measure the dynamic interactions of the com-
ponentsofbloodwiththenovelhaemodialysismembrane
as well as to quantify the extraction of the anions by
measuring the amounts of anions actually extracted.
4. CONCLUSIONS
The overall picture that emerges from this study is that
thepresentPPy–cellulosecompositeisapromisinghaemo-
dialysis membrane material, regarding both toxin removal
performance and haemocompatibility. We have demon-
strated the feasibility of using potential-controlled ion
exchange properties of both non-heparinized and hepari-
nized composites to remove small size uraemic toxins.
Furthermore, no change in the ion exchange capacity
could be detected after heparinizing the material. The
thrombogenic properties of the composite were improved
by applying a ﬁrst generation of stable heparin coating on
the material surface. Thus, in terms of platelet adhesion
and thrombin generation, the heparinized composite is
not different from the haemocompatible synthetic polymer
PS. Moreover, the pro-inﬂammatory characteristics of the
composite were, to some extent, superior to commercially
available haemodialysis membranes.
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committee.
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